MAP2K7 and hematopoietic and lymphoid cell neoplasm: A variety of other kinase inhibitors are used or in trials for hematologic cancers (e.g. PI3K inhibitors like idelalisib, BCL2 inhibitor venetoclax, MEK inhibitors in trials for certain leukemias).